Lambodies with high affinity and selectivity for glycans and uses therefor

US10036747B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10036747-B2
Application numberUS-201214359653-A
CountryUS
Kind codeB2
Filing dateNov 21, 2012
Priority dateNov 22, 2011
Publication dateJul 31, 2018
Grant dateJul 31, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to dimeric proteins comprised of subunits having (i) recombinant lamprey variable lymphocyte receptor (VLR) diversity regions linked to (ii) multimerization domains. The dimeric proteins exhibit binding specificity for glycosylated antigens, and they may be used in methods of detecting or isolating glycans from a sample, and in methods of disease diagnosis, prognosis, progression monitoring, treatment, and imaging.

First claim

Opening claim text (preview).

What is claimed is: 1. A lambody, wherein the lambody comprises a first recombinant lambody subunit and a second recombinant lambody subunit, wherein each recombinant lambody subunit is a fusion protein consisting of a lamprey variable lymphocyte receptor (VLR) diversity region linked via an amide bond to a multimerization domain, wherein the VLR diversity region is SEQ ID NO:2, SEQ ID NO:4, or the variant of SEQ ID NO:2 with the five amino acid mutations S19N, S86G, H105R, K112M and T208S, said variant differing from SEQ ID NO:2 only by the five amino acid mutations, wherein the lambody subunits are dimerized via their multimerization domains, and wherein the lambody exhibits binding specificity for a glycan, glycolipid or glycoprotein. 2. The lambody of claim 1 , wherein the VLR diversity regions of the first and second recombinant lambody subunits have identical amino acid sequences. 3. The lambody of claim 1 , wherein the VLR diversity regions of the first and second recombinant lambody subunits have different amino acid sequences. 4. The lambody of claim 1 , wherein the lambody exhibits a binding affinity (K D ) of at least about 1×10 −7 M for a target against which it exhibits binding specificity. 5. The lambody of claim 1 , wherein the multimerization domain is selected from the group consisting of a yeast leucine zipper dimerization domain, a partial antibody hinge region and leucine zipper dimerization domain, a coil-coiled dimerization peptide, and an antibody Fc fragment. 6. A lambody multimer, wherein the lambody multimer comprises three or more multimerized recombinant lambody subunits, wherein the recombinant lambody subunits are each fusion proteins consisting of a lamprey variable lymphocyte receptor (VLR) diversity region linked via an amide bond to a multimerization domain, wherein the VLR diversity region is SEQ ID NO:2, SEQ ID NO:4, or the variant of SEQ ID NO:2 with the five amino acid mutations S19N, S86G, H105R, K112M and T208S, said variant differing from SEQ ID NO:2 only by the five amino acid mutations, wherein the lambody subunits are multimerized via their multimerization domains, and wherein the lambody multimer exhibits binding specificity for a glycan, glycolipid or glycoprotein. 7. The lambody multimer of claim 6 , wherein the multimerization domain is selected from the group consisting of a yeast leucine zipper dimerization domain, a partial antibody hinge region and leucine zipper dimerization domain, a coil-coiled dimerization peptide, and an antibody Fc fragment. 8. A recombinant lambody subunit, wherein the recombinant lambody subunit is a fusion protein consisting of a lamprey variable lymphocyte receptor (VLR) diversity region linked via an amide bond to a multimerization domain, wherein the VLR diversity region is SEQ ID NO:2, SEQ ID NO:4, or the variant of SEQ ID NO:2 with the five amino acid mutations S19N, S86G, H105R, K112M and T208S, said variant differing from SEQ ID NO:2 only by the five amino acid mutations, wherein the lambody subunit exhibits binding specificity for a glycan, glycolipid or glycoprotein. 9. The recombinant lambody subunit of claim 8 , wherein the multimerization domain is selected from the group consisting of a yeast leucine zipper dimerization domain, a partial antibody hinge region and leucine zipper dimerization domain, a coil-coiled dimerization peptide, and an antibody Fc fragment. 10. A method for isolating a glycan-bearing element from a sample, said method comprising (i) adhering a recombinant lambody subunit, lambody or lambody multimer to a support, (ii) contacting the support with a sample under conditions permitting binding of a glycan of the glycan-bearing element in the sample by a VLR diversity region of a recombinant lambody subunit, lambody or lambody multimer adhered to the support, (iii) washing unbound sample from the support, (iv) eluting the glycan-bearing element from the support, and (v) collecting the glycan-bearing element, wherein the recombinant lambody subunit is a fusion protein consisting of a lamprey variable lymphocyte receptor (VLR) diversity region linked via an amide bond to a multimerization domain, wherein the VLR diversity region is SEQ ID NO:2, SEQ ID NO:4, or the variant of SEQ ID NO:2 with the five amino acid mutations S19N, S86G, H105R, K112M and T208S, said variant differing from SEQ ID NO:2 only by the five amino acid mutations, and wherein the lambody subunit exhibits binding specificity for a glycan, glycolipid or glycoprotein; wherein the lambody comprises a first recombinant lambody subunit and a second recombinant lambody subunit, wherein each recombinant lambody subunit is a fusion protein consisting of a lamprey variable lymphocyte receptor (VLR) diversity region linked via an amide bond to a multimerization domain, wherein the VLR diversity region is SEQ ID NO:2, SEQ ID NO:4, or the variant of SEQ ID NO:2 with the five amino acid mutations S19N, S86G, H105R, K112M and T208S, said variant differing from SEQ ID NO:2 only by the five amino acid mutations, wherein the lambody subunits are dimerized via their multimerization domains, and wherein the lambody exhibits binding specificity for a glycan, glycolipid or glycoprotein; and wherein the lambody multimer comprises three or more multimerized recombinant lambody subunits, wherein the recombinant lambody subunits are each fusion proteins consisting of a lamprey variable lymphocyte receptor (VLR) diversity region linked via an amide bond to a multimerization domain, wherein the VLR diversity region is SEQ ID NO:2, SEQ ID NO:4, or the variant of SEQ ID NO:2 with the five amino acid mutations S19N, S86G, H105R, K112M and T208S, said variant differing from SEQ ID NO:2 only by the five amino acid mutations, wherein the lambody subunits are multimerized via their multimerization domains, and wherein the lambody multimer exhibits binding specificity for a glycan, glycolipid or glycoprotein. 11. The method of claim 10 , wherein the support is a bead in a column. 12. A method for detecting a glycan, glycolipid or glycoprotein in a biological sample from a subject, said method comprising (i) contacting a biological sample from a subject with a recombinant lambody subunit, lambody or lambody multimer under conditions permitting binding of the glycan, glycolipid or glycoprotein by a VLR diversity region of the recombinant lambody subunit, lambody or lambody multimer, and (ii) detecting binding by the VLR diversity region of the recombinant lambody subunit, lambody or lambody multimer to the glycan, glycolipid or glycoprotein in the sample, wherein the recombinant lambody subunit is a fusion protein consisting of a lamprey variable lymphocyte receptor (VLR) diversity region linked via an amide bond to a multimerization domain, wherein the VLR diversity region is SEQ ID NO:2, SEQ ID NO:4, or the variant of SEQ ID NO:2 with the five amino acid mutations S19N, S86G, H105R, K112M and T208S, said variant differing from SEQ ID NO:2 only by the five amino acid mutations, and wherein the lambody subunit exhibits binding specificity for a glycan, glycolipid or glycoprotein; wherein the lambody comprises a first recombinant lambody subunit and a second recombinant lambody subunit, wherein each recombinant lambody subunit is a fusion protein consisting of a lamprey variable lymphocyte receptor (VLR) diversity region linked via an amide bond to a multimerization domain, wherein the VLR diversity region is SEQ ID NO:2, SEQ ID NO:4, or the variant of SEQ ID NO:2 with the five amino acid mutations S19N, S86G, H105R, K112M and T208S, said variant differing from SEQ ID NO:2 only by the five amino acid mutations, wherein the lambody subunits are dimerized via their mu

Assignees

Inventors

Classifications

  • for cancer · CPC title

  • involving antibodies to sugar part of glycoproteins · CPC title

  • for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites · CPC title

  • containing domain for protein-protein interaction · CPC title

  • from fish · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10036747B2 cover?
The invention relates to dimeric proteins comprised of subunits having (i) recombinant lamprey variable lymphocyte receptor (VLR) diversity regions linked to (ii) multimerization domains. The dimeric proteins exhibit binding specificity for glycosylated antigens, and they may be used in methods of detecting or isolating glycans from a sample, and in methods of disease diagnosis, prognosis, prog…
Who is the assignee on this patent?
Univ Maryland
What technology area does this patent fall under?
Primary CPC classification G01N33/566. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).